RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Edouard Louis  ¹     Remo Panaccione  ²     Gareth Parkes  ³     Laurent Peyrin-Biroulet  ⁴     Marc Ferrante  ⁵     Ken Takeuchi  ⁶     Britta Siegmund  ⁷     Phillip Levine  ⁸     Jasmina Kalabic  ⁹     Ezequiel Neimark     Kori Wallace  ¹⁰     Su Chen     Rachel Duan     Alessandro Armuzzi  ¹¹     Luc Biedermann  ¹²     Edward V. Loftus  ¹³     Gil Y. Melmed  ¹⁴     Stefan Schreiber  ^15    
1 University Hospital CHU of Liège, Liège, Belgium
² University of Calgary, Calgary, Canada
³ Barts Health NHS Trust, London, United Kingdom
⁴ University Hospital of Nancy, Lorraine University, Vandoeuvre, France
⁵ University Hospitals Leuven, Leuven, Belgium
⁶ Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
⁷ Berlin Institute of Health, Berlin, Germany
⁸ AbbVie, Inc., North Chicago, United States
⁹ AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
¹⁰ AbbVie, Inc, North Chicago, United States
¹¹ IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
¹² USZ Zürich, Zürich, Switzerland
¹³ Mayo Clinic College of Medicine, Rochester, United States
¹⁴ Cedars Sinai Medical Center, Los Angeles, United States
¹⁵ University Hospital Schleswig-Holstein, Kiel, Germany

Topic
Endoscopy, IBD

Session
IL-23-Blockers in IBD: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)